A randomized, multicenter, double-blind, placebo-controlled, dose- finding study of org 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer

Gynecologic Oncology

Volumn 67, Issue 2, 1997, Pages 172-177

  Roberts, James A ^a   Jenison, Eric L ^b   Kim, Kyungmann ^c   Clarke Pearson, Daniel ^d   Langleben, Adrian ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AKRON GENERAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; CISPLATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROPATHY; OVARY CANCER; PERCEPTIVE THRESHOLD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIBRATION SENSE;

EID: 0031282054     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4832     Document Type: Article

References (20)

1. Thompson S W, Davis L E, Kornfeld M, Hilgers R D, Standefer J T. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic and toxicologic studies. Cancer. 54:1984;1269-1275.
2. Mollman J E, Glover D J, Hogan W M, Furman R E. Cisplatin neuropathy. Risk factors, prognosis and protection by WR-2721. Cancer. 61:1988;2192-2195.
3. Levin L, Hryniuk W. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 5:1987;756-767.
4. Ozols R, Corden B, Jacob J, Wesley M, Ostchega Y, Young R. High-dose cisplatin in hypertonic saline. Ann Int Med. 100:1984;19-24.
5. Kaplan R S, Wiernik P H. Neuropathy of antineoplastic drugs. Semin Oncol. 9:1982;103-130.
6. Cowan J D, Kies M S, Roth J L, Joyce R P. Nerve conduction studies in patients treated withcis. Cancer Treat Rep. 64:1980;1119-1122.
7. Becher R, Schutt P, Osieka R, Schmidt C G. Peripheral neuropathy and ophthalmologic toxicity after treatment withcis. J Cancer Res Clin Oncol. 96:1980;219-221.
8. Neijt J P, Ten Bokkel Huinink W W, van der Burg M EL. Randomized trial comparing two chemotherapy regimens (Hexa-CAF vs CLAP-5) in advanced ovarian cancer. Lancet. II:1984;594-600.
9. Ozols R, Ostchega Y, Myers C, Young R. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol. 3:1985;1246-1250.
10. Bijlsma W A, Jennekens F GI, Schotman P, Gispen W H. Neurotropic factors and regeneration in the peripheral nervous system. Psychoneurendocrinology. 1984;199-215.
11. P, DeKoning, W, H, Gispen, 1987, A Rationale for the Use of Melanocortins in Neural Damage, Pharmacological Approaches to Brain and Spinal Cord Injury, 12, 233, 258, Plenum, New York.
12. De Wied D, Jolles J. Neuropeptides derived from pro-opiocortin behavioral physiological and neurochemical effects. Physiol Rev. 62:1982;976-1059.
13. F, L, Strand, C, H, Smith, 1986, LPH, MSH, ACTH and Motorsystem, Neuropeptides and Behaviour, D, de WierW, H, GispenT, B, van WiemersmaT, B, Greidanus, 247, 281, Pergamon, Elmsford, NY.
14. Edwards P M, van der Zee C EEM, Verhagen J, Schotman P, Jennekens F GI, Gispen W H. Evidence that the neurotropic actions of alpha-MSH may derive from its ability to mimic action of a peptide formed in degenerating nerve stumps. J Neurol Sci. 64:1984;333-340.
15. Gerritsen van der Hoop R, Vecht C J, van den Burg M EL, Elderson A, Haanstra W, Boogerd F, Heimans J J, Vries E P, van Houwelingen J C, Jennekens F GI, Gispen W H, Neijt J P. An ACTH (4-9) analog prevents cisplatin induced neuropathy in ovarian cancer patients. N Engl J Med. 322:1990;89-94.
16. Elderson A, Gerritsen van der hoop R, Haanstra W, Neijt J P, Gispen W H, Jennekens F GL. Vibration perception and thermoperception as quantitative measurement in the monitoring of cisplatin induced neuropathy. J Neurol Sci. 93:1989;167-174.
17. J, Cohen, 1977, Statistical Power Analysis for the Behavior Sciences, Academic Press, New York.
18. Ongerboer de Visser B W, Tiessens G. Polyneuropathy induced by cisplatin. Prog Exp Tumor Res. 29:1985;190-196.
19. Hadley D, Herr H W. Peripheral neuropathy associated withcis. Cancer. 44:1979;2026-2028.
20. Hovestadt A, van der Burg M EL, Verbiest H BC, van Putten W LJ, Vecht C J. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo. J Neurol. 239:1992;143-146.